Game-changing has tremendous implications for pharmaceutical companies and its professionals. As the US and European pharmaceutical industry continues to transition through the mature or competitive stage of its life cycle, it is more important than ever for companies to play the game at which they excel. Pharmaceutical professionals at every level of the company need to understand the types and techniques of game-changers in order to identify and execute their own game-changing strategies and tactics.
Game-Changing InnovationsWhat is a "game-changer"? Game-changers like Apple are rule-breakers: they disrupt the industry's status quo and conduct a market makeover in order to play the game on a field where they can win decisively. The best game-changers actually evolve to become "game-makers." Game-makers dictate how business is done in their sector: they make the rules for other industry competitors to follow. Procter & Gamble, Coke, and Microsoft were all once game-changers that evolved to dominate their respective industries. Apple is seeking to become a game-maker in digital music by controlling the digital music format, ensuring its iPod is the only portable music player compatible with songs purchased from the company's iTunes music store, and by tightly managing its selected set of suppliers.
Most game-changing companies transform a market by using one of three types of innovations: product, technology, or business model innovations.
Apple was able to change the music industry by combining two different types of innovations: product (iPod) and technology (digital music downloads).
Products and Technology
Pharmaceutical companies have traditionally focused on product and technology innovations. For example, GSK created the world's best-selling asthma agent and combination product Advair (fluticasone/salmeterol) by developing the diskus, a novel inhalation delivery device. Allergan has become a specialty pharmaceuticals market leader by adapting two therapeutic products into first-in-class cosmetic products: wrinkle-reducing agent Botox was initially used for the treatment of strabismus or crossed eyes; eyelash enhancer Latisse was originally approved to manage glaucoma. Light Sciences Oncology is seeking to change the cancer treatment paradigm by using a drug that is activated by a special light targeted within a solid tumor. Its photo-therapy device Litx is currently undergoing Phase III trials for the treatment of metastatic colorectal cancer and hepatocellular carcinoma.
Genentech and Amgen have been leaders in the industry-changing biotechnologies of monoclonal antibodies and recombinant proteins, respectively. Roche was quick to invest in and ultimately acquire Genentech for its expertise, which has resulted in the development of several blockbuster oncology products, including Avastin and Herceptin. By leveraging this acquisition and other capabilities, Roche is now poised to become an industry game-changer; it is the dominant player in the global oncology market—the largest market in the world. According to Decision Resources, Roche will be the only top 10 pharmaceutical company with overall US growth rates exceeding 3 percent during the next five years.